On November 11, 2021 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that the company will participate in the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium (Press release, Personalis, NOV 11, 2021, View Source [SID1234595290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will showcase the Personalis NeXT Platform which enables comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The NeXT Platform can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Following is a list of abstracts that will be presented online at the meeting.

Scientific Poster Presentations

Poster Number & Category

Title & Presenter

Day & Time

19

Biomarkers, Immune Monitoring, and Novel Technologies

Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST

Presenter: Charles W. Abbott, PhD

NOV 12 -14 | Online

20

Biomarkers, Immune Monitoring, and Novel Technologies

Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy

Presenter: Charles W. Abbott, Ph.D.

NOV 12 -14 | Online

75

Biomarkers, Immune Monitoring, and Novel Technologies

Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome

Presenter: Eric Levy, PhD

NOV 12 -14 | Online

79

Biomarkers, Immune Monitoring, and Novel Technologies

Extensively validated HLA LOH algorithm demonstrates an association between HLA LOH and genomic instability

Presenter: Rachel M. Pyke, PhD

NOV 12 -14 | Online

Following are details of an industry-sponsored symposium which will be presented online at the meeting.

Industry Sponsor Symposium

Presentation Category

Title & Presenter

Day & Time

Sponsored Symposia

Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy

Presenter: Erin N. Newburn, PhD

NOV 12 | 1:30 – 2:00 PM EST

Personalis will also be exhibiting during the online portion of conference. Representatives will be available online to answer questions about the company’s cancer immunogenomics services.

On November 11, 2021 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported that the Company will present at the 2021 Jefferies London Healthcare Conference (Press release, Fusion Pharmaceuticals, NOV 11, 2021, View Source [SID1234595308]). A recording of the presentation will be made available for on-demand viewing on Thursday, November 18, 2021 at 8:00am GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On November 11, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported the financial results and corporate updates for the first nine months 2021 (Press release, Evotec, NOV 11, 2021, View Source [SID1234595240]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HIGHLIGHTS
STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT
Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up 26%
Milestone revenues of € 27.9 m well above last year (9M 2020: € 8.4 m)
Just – Evotec Biologics contributed € 34.7 m to revenues; 43% above last year’s level of € 24.3 m
Strong progress in both segments: Total EVT Execute revenues up 17% to € 429.8 m (9M 2020: € 367.5 m); EVT Innovate revenues up 35% to € 101.9 m (9M 2020: € 75.7 m)
Adjusted Group EBITDA of € 70.1 m (9M 2020: € 76.9 m) primarily driven by higher costs of sales ahead of production start of J.POD Redmond (US), a deliberate increase in unpartnered R&D (up 28%), the overall growth of Evotec and effects from the US public offering; like-for-like growth (excluding portfolio and fx effects) would have reached 16%.
Other non-operating result increased significantly to € 228.8 m (9M 2020: € (15.9) m) mainly due to fair value adjustments of the equity participation in Exscientia Ltd.

DATA-DRIVEN AUTOBAHN TO CURES: STRONG PROGRESS IN ALL LANES
Several new and extended drug discovery and development agreements in all areas
Just – Evotec Biologics opened J.POD Redmond (US); start operations on track; project initiation of J.POD Toulouse (France) in 2021
Positive Phase IIb results in refractory chronic cough for eliapixant reported by partner Bayer
Excellent progress in iPSC and protein degradation collaborations with Bristol Myers Squibb ("BMS"); Opt-in for EVT8683 to enter clinical development
Kazia Therapeutics Limited has commenced enrolment to a Phase I clinical trial of EVT801, an investigational cancer therapy (after period-end)
Successful NASDAQ IPO of EVOequity portfolio company and partner Exscientia Ltd (after period-end); Series B extension by Evotec’s first spin-off Topas Therapeutics

CORPORATE
Closing of public offering at NASDAQ on 08 November 2021, with notice from underwriters on 05 November 2021 of their intention to partially exercise their option to purchase additional ADSs (after period-end)

CONFIRMATION OF BUSINESS OUTLOOK FOR FULL-YEAR 2021 AND MID-TERM TARGETS 2025
Group revenues expected to be in a range of € 550 – 570 m (€ 565 – 585 m at constant exchange rates) (2020: € 500.9 m)
Adjusted Group EBITDA expected to be in the range of € 105 – 120 m (€ 115 – 130 m at constant exchange rates) (2020: € 106.6 m)
Unpartnered research and development expenses expected to be in a range of € 50 – 60 m (2020: € 46.4 m)
Mid-term goals target revenue growth to > € 1,000 m, adjusted EBITDA of ≥ € 300 m and unpartnered research and development expenses of > € 100 m by 2025

Given current global insecurities surrounding the COVID-19 pandemic, a likely negative impact – though less pronounced than in 2020 – is already estimated within the guidance for revenues and adjusted EBITDA stated above.

More detailed information and financial tables are available in our nine-month report published on the Evotec website under the following link:

View Source

WEBCAST / CONFERENCE CALL
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

A simultaneous slide presentation for participants dialling in via phone is available at View Source

Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage View Source shortly before the event.

The access code is 315614529#. The on-demand version of the webcast will be available on our website: View Source and under the direct link View Source

On November 11, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that Lantern Pharma’s abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in person and virtually from November 18-21, 2021 (Press release, Lantern Pharma, NOV 11, 2021, View Source [SID1234595257]). The abstract is available online on the SNO website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: LP-184, a novel alkylating agent, is effective in Glioblastoma
Abstract ID: EXTH-16
Submission type: Adult
Abstract Tumor Type: Glial Tumors
Abstract Category: Preclinical Experimental Therapeutics
Poster Session Date & Time: Friday, November 19, 2021, 7:30 PM – 9.30 PM EST
Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma

The abstract submitted by Lantern Pharma and researchers at The Kennedy Krieger Institute affiliated with Johns Hopkins School of Medicine describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo glioblastoma models. The abstract also highlights the increased efficacy of LP-184 in MGMT unmethylated GBM, an area of large unmet clinical need, as well as the predicted synthetic lethality of LP-184 in GBM with DNA damage repair deficiencies such as decreased expression of nucleotide excision repair components ERCC3/6. The poster displays the favorable blood brain barrier crossing properties of LP-184 evaluated in vivo, suggesting that the maximum brain concentration achieved after a single intravenous infusion of LP-184 in mice is greater than that required for growth inhibition of sensitive GBM cells. These findings identify LP-184 as a promising new alkylating agent and support its further development for GBM therapy.

Electronic poster presentation files will be captured electronically (in PDF) prior to the meeting and available on the mobile meeting app, website and onsite. Accepted abstracts will be published as a proceedings supplement in Neuro-Oncology, the official journal of the SNO after the completion of the meeting.

LP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that overexpress certain biomarkers and is therefore lethal in tumors that harbor mutations in DNA repair pathways or have deficiency in these pathways because of low expression of genes required for DNA repair. LP-184 is being developed for several targeted central nervous system cancer indications, including glioblastoma. LP-184 has recently been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of malignant gliomas, as well as pancreatic cancer.

On November 11, 2021 Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, reported that the Company will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021 (Press release, Silverback Therapeutics, NOV 11, 2021, View Source [SID1234595291]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback’s President and Chief Scientific Officer, will participate in a fireside chat on Wednesday, November 17, 2021 at 2:40 PM ET (11:40 AM PT). The live webcast of the event will be available on Silverback’s investor relations website and a replay will be available for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.